PE-22-28 dosage chart

Reconstitution steps

1. 1Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. 2Inject slowly down the vial wall; avoid foaming.
3. 3Gently swirl/roll until dissolved (do not shake).
4. 4Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a sharps container immediately.
• Rotate injection sites (abdomen, thighs, upper arms) systematically to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle to prevent leakage.
• Document daily dose, site rotation, and any observations to maintain protocol consistency.
• Given PE-22-28’s high potency (IC50 ~0.12 nM), conservative dosing is recommended; most preclinical effects occurred at low microgram ranges.

How This Works

PE-22-28 functions as a potent and selective antagonist of TREK-1 (KCNK2) two-pore domain potassium channels. By blocking TREK-1, it depolarizes neurons and enhances excitability, leading to increased firing of serotonergic neurons and elevated monoamine neurotransmission. This mechanism produces rapid antidepressant-like effects in preclinical models—within 4 days, PE-22-28 significantly increases hippocampal neurogenesis and synaptogenesis markers, changes typically requiring weeks with conventional antidepressants. The peptide also activates CaMKII/CREB pathways that promote neuronal survival and plasticity. PE-22-28 represents a shortened, optimized analog of spadin with superior potency (IC50 ~0.12 nM versus 40–60 nM for spadin) and longer duration of action (~23 hours versus ~7 hours). Notably, research also demonstrates neuroprotective effects in stroke models through biphasic dosing that leverages both TREK-1 activation at ultra-low doses and inhibition at standard doses.

Potential Benefits & Observed Safety Profile

Observations from preclinical literature and mechanistic studies.

• Rapid Antidepressant Effects: Produces behavioral improvements within 4 days in rodent models; reduces immobility in forced swim tests and decreases latency to feed in novel environments.
• Enhanced Neuroplasticity: Increases hippocampal neurogenesis, synaptogenesis markers (PSD-95), dendritic spine density, and BDNF expression within days.
• Neuroprotection: In stroke models, preserves dopaminergic neurons, reduces motor deficits, and prevents post-stroke depressive behavior.
• Favorable Safety Profile: Shows high selectivity with no effects on hERG channels (cardiac safety), no impact on heart rate, blood pressure, glucose regulation, or pain perception in preclinical studies. No TREK-1-related side effects or withdrawal observed.
• No Human Data: All evidence is from cell culture and animal studies; human safety and pharmacokinetics remain unestablished.
• Potential Mild Reactions: Subcutaneous administration may occasionally cause minor injection-site reactions (slight redness or tenderness).

Lifestyle Factors

Complementary strategies to support neuroplasticity and mood optimization.

• Maintain consistent sleep schedule and prioritize 7–9 hours of quality sleep to support neurogenesis.
• Engage in regular physical activity; both aerobic exercise and resistance training enhance BDNF and mood-regulating pathways.
• Follow a nutrient-dense diet rich in omega-3 fatty acids, antioxidants, and B-vitamins to support brain health.
• Practice stress-management techniques (meditation, mindfulness, therapy) to complement neuroplastic adaptations.
• Consider cognitive training or novel learning activities to synergize with enhanced synaptic plasticity.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

• Clean the vial stopper and injection site with alcohol; allow both to air-dry completely.
• Pinch a skinfold of subcutaneous tissue; insert the needle at 45° (or 90° if using very short needles with ample subcutaneous fat).
• Do not aspirate for subcutaneous injections; inject solution slowly and steadily.
• Rotate sites systematically (abdomen at least 2 inches from navel, front/outer thighs, outer upper arms) to prevent lipohypertrophy and maintain absorption consistency.
• Given the very small injection volumes (often ≤0.10 mL), technique precision is critical. Consider using 30- or 50-unit insulin syringes for doses under 10 units to improve measurement accuracy.
• Withdraw needle at the same angle inserted; apply gentle pressure if needed; dispose of syringe immediately in sharps container.

important-note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. PE-22-28 is a research peptide not FDA-approved for human use. All information is derived from preclinical studies; no human clinical trials have been published. Consult qualified healthcare professionals before considering any experimental compounds.

PE-22-28 dosage FAQs